The UK and US have reached a significant commercial pact that will maintain no duties on British medicine exports going into the American market.
Key Provisions of the Pact
As part of the deal, the UK has pledged to increase funding on medicines through the NHS. This move secures that duties on these vital goods will stay at nothing for a period of three years.
This development comes after earlier threats to dramatically increase import taxes on branded drug imports, with increases floated up to 100%.
"This deal between the Britain bolsters the global environment for innovative medicines and introduces much-needed equity to transatlantic drug exports," a release declared.
Economic Importance
Drugs are one of the UK's biggest goods shipped to the America, which is easily the largest destination for large British pharmaceutical firms.
Statistics reveal that in the one-year period to the end of last September, the UK shipped pharmaceutical products valued at £11.1bn to the US. This value accounted for a significant portion of all goods exports in that span.
"This deal secures work, stimulates funding and sets the stage for the UK to emerge as a international leader for biotech and pharma," a minister commented.
Specific British Pledges
The pact includes several specific pledges from the British government:
- Higher Cost Ceiling: The UK will lift the price threshold at which it judges new therapies to be unaffordable by twenty-five percent.
- Increased NHS Spending: There is a aim to increase overall NHS spending on drugs from 0.3% of GDP to 0.6 percent over the following ten-year period.
- Payback Limit: The percentage manufacturers must return to the NHS to control costs will be restricted at fifteen percent. Last year, refunds topped twenty percent.
Recent Tensions
This agreement comes amid a long-running tension between the pharmaceutical industry and the ministers over spending levels and NHS adoption.
These tensions were heightened by claims that US patients were paying a premium for the equivalent treatments than people in the Britain and the EU.
Over the last 18 months, several significant manufacturing plans in the UK have been paused or cancelled, while multi-billion-dollar expansions have been directed toward US facilities.
A senior figure acknowledged that the NHS needed to invest a greater share on treatments, noting that its spending on drugs had decreased as a proportion of its total funding over the last ten years.
